Vol 9, No 5 (2020)
Research paper
Published online: 2020-09-23

open access

Page views 818
Article views/downloads 635
Get Citation

Connect on Social Media

Connect on Social Media

The association of oxidative stress with serum irisin and betatrophin in pregnant women with gestational diabetes mellitus

Fatma Beyazit1, Kübra Özkan Karacaer1, Hakan Turkon2
Clin Diabetol 2020;9(5):328-334.

Abstract

Background. Irisin and betatrophin are polypeptide hormones implicated in glucose metabolism and insulin resistance (IR). Gestational diabetes mellitus (GDM) is accompanied by oxidative stress (OS) and the association between circulating irisin and betatrophin levels and GDM is controversial. The present study aimed to investigate the association of second-trimester irisin, betatrophin concentrations and their correlations between serum OS markers in GDM patients. Methods. The study included 45 GDM patients and 45-age matched pregnant women as controls. Serum fasting glucose, HOMA-IR, ischemia modified albumin (IMA), total oxidative stress (TOS), total antioxidant status (TAS), oxidative stress index (OSI), irisin and betatrophin were measured. Results. Serum irisin levels were decreased and TOS and OSI levels were found to be increased in the patient group. No significant difference was found with respect to serum betatrophin and IMA levels between study groups. A correlation analysis revealed no correlation between serum irisin and other assessed variables. Conclusions. Gestational diabetes mellitus is an OS condition in addition to being a metabolic disease. Although not correlated with OS, irisin but not betatrophin may be a useful biomarker to predict GDM.

Article available in PDF format

View PDF Download PDF file

References

  1. Al-Ghazali MJ, Ali HA, Al-Rufaie MM. Serum irisin levels as a potential marker for diagnosis of gestational diabetes mellitus. Acta Biomed. 2020; 91(1): 56–63.
  2. Ma Sg, Yu Wn, Jin Y, et al. Evaluation of serum ischemia-modified albumin levels in pregnant women with and without gestational diabetes mellitus. Gynecol Endocrinol. 2012; 28(11): 837–840.
  3. Li YT, Kuo TC, Wang PH. Low serum level of irisin and gestational diabetes mellitus. Taiwan J Obstet Gynecol. 2019; 58(4): 443–444.
  4. Khambule L, George JA. The Role of Inflammation in the Development of GDM and the Use of Markers of Inflammation in GDM Screening. Adv Exp Med Biol. 2019; 1134: 217–242.
  5. Wang P, Ma HH, Hou XZ, et al. Reduced plasma level of irisin in first trimester as a risk factor for the development of gestational diabetes mellitus. Diabetes Res Clin Pract. 2018; 142: 130–138.
  6. Yuksel MA, Oncul M, Tuten A, et al. Maternal serum and fetal cord blood irisin levels in gestational diabetes mellitus. Diabetes Res Clin Pract. 2014; 104(1): 171–175.
  7. Kuzmicki M, Telejko B, Lipinska D, et al. Serum irisin concentration in women with gestational diabetes. Gynecol Endocrinol. 2014; 30(9): 636–639.
  8. Ebert T, Kralisch S, Wurst U, et al. Betatrophin levels are increased in women with gestational diabetes mellitus compared to healthy pregnant controls. Eur J Endocrinol. 2015; 173(1): 1–7.
  9. Niki H, Kishimoto Y, Ibe S, et al. Associations Between Plasma Betatrophin Levels and Coronary and Peripheral Artery Disease. J Atheroscler Thromb. 2019; 26(6): 573–581.
  10. Ye J, Qin Yu, Wang D, et al. The Relationship between Circulating ANGPTL8/Betatrophin Concentrations and Adult Obesity: A Meta-Analysis. Dis Markers. 2019; 2019: 5096860.
  11. Battal F, Türkön H, Aylanç N, et al. Investigation of Blood Betatrophin Levels in Obese Children with Non-Alcoholic Fatty Liver Disease. Pediatr Gastroenterol Hepatol Nutr. 2018; 21(2): 111–117.
  12. Li S, Liu D, Li L, et al. Circulating Betatrophin in Patients with Type 2 Diabetes: A Meta-Analysis. J Diabetes Res. 2016; 2016: 6194750.
  13. Li H, Yin Q, Li N, et al. Plasma Markers of Oxidative Stress in Patients with Gestational Diabetes Mellitus in the Second and Third Trimester. Obstet Gynecol Int. 2016; 2016: 3865454.
  14. Usluoğullari B, Usluogullari CA, Balkan F, et al. Role of serum levels of irisin and oxidative stress markers in pregnant women with and without gestational diabetes. Gynecol Endocrinol. 2017; 33(5): 405–407.
  15. Mohsen L, Akmal DM, Ghonaim EK, et al. Role of mean platelet volume and ischemia modified albumin in evaluation of oxidative stress and its association with postnatal complications in infants of diabetic mothers. J Matern Fetal Neonatal Med. 2018; 31(14): 1819–1823.
  16. Ozler S, Oztas E, Uygur D, et al. The Value of Total antioxidant Status and Serum Tumor Necrosis Factor-α Levels at 24-28 Weeks of Gestation in the Prediction of Optimal Treatment Protocol in Gestational Diabetes Mellitus. Exp Clin Endocrinol Diabetes. 2019; 127(7): 485–491.
  17. Metzger BE, Gabbe SG, Persson B, et al. International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010; 33(3): 676–682.
  18. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412–419.
  19. Jansen EH, Ruskovska T. Comparative Analysis of Serum (Anti)oxidative Status Parаmeters in Healthy Persons. Int J Mol Sci. 2013; 14(3): 6106–6115.
  20. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med. 2000; 19(4): 311–315.
  21. Pérez-Sotelo D, Roca-Rivada A, Baamonde I, et al. Lack of Adipocyte-Fndc5/Irisin Expression and Secretion Reduces Thermogenesis and Enhances Adipogenesis. Sci Rep. 2017; 7(1): 16289.
  22. Ebert T, Stepan H, Schrey S, et al. Serum levels of irisin in gestational diabetes mellitus during pregnancy and after delivery. Cytokine. 2014; 65(2): 153–158.
  23. Sancak S, Aydin H, Sargin M, et al. Serum irisin level increases throughout the gestational period and it does not play role in development of gestational diabetes mellitus. Acta Endocrinol (Buchar). 2017; 13(4): 393–399.
  24. Kong FJ, Ma LL, Li G, et al. PLOS ONE Staff Correction: Circulating Betatrophin Levels and Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis. PLoS One. 2017; 12(2): e0172449.
  25. Niki H, Kishimoto Y, Ibe S, et al. Associations Between Plasma Betatrophin Levels and Coronary and Peripheral Artery Disease. J Atheroscler Thromb. 2019; 26(6): 573–581.
  26. Battal F, Türkön H, Aylanç N, et al. Investigation of Blood Betatrophin Levels in Obese Children with Non-Alcoholic Fatty Liver Disease. Pediatr Gastroenterol Hepatol Nutr. 2018; 21(2): 111–117.
  27. Huang Y, Fang C, Ma Z, et al. Betatrophin Levels were Increased in Pregnant Women with or without Gestational Diabetes Mellitus and Associated with Beta Cell Function. Rev Bras Ginecol Obstet. 2016; 38(6): 287–292.
  28. Wawrusiewicz-Kurylonek N, Telejko B, Kuzmicki M, et al. Increased Maternal and Cord Blood Betatrophin in Gestational Diabetes. PLoS One. 2015; 10(6): e0131171.
  29. Erol O, Ellidağ HY, Ayık H, et al. Evaluation of circulating betatrophin levels in gestational diabetes mellitus. Gynecol Endocrinol. 2015; 31(8): 652–656.
  30. Xie X, Gao H, Wu S, et al. Increased Cord Blood Betatrophin Levels in the Offspring of Mothers with Gestational Diabetes. PLoS One. 2016; 11(5): e0155646.
  31. Pan R, Zhang H, Yu S, et al. Betatrophin for diagnosis and prognosis of mothers with gestational diabetes mellitus. J Int Med Res. 2019; 47(2): 710–717.
  32. Eraldemir FC, Üren N, Kum T, et al. Association of Serum Paraoxonase 1 Activities, Polymorphisms and Oxidative Stress in Breast Cancer Patients with Type 2 Diabetes Mellitus. J Med Biochem. 2019; 38(3): 368–375.
  33. Xiang M, Feng J, Geng L, et al. Sera total oxidant/antioxidant status in lung cancer patients. Medicine (Baltimore). 2019; 98(37): e17179.
  34. Bhat MA, Gandhi G. Elevated oxidative DNA damage in patients with coronary artery disease and its association with oxidative stress biomarkers. Acta Cardiol. 2019; 74(2): 153–160.
  35. Zhou Mi, Liu XH, Liu QQ, et al. Lactonase Activity, Status, and Genetic Variations of Paraoxonase 1 in Women with Gestational Diabetes Mellitus. J Diabetes Res. 2020; 2020: 3483427.
  36. Usluoğullari B, Usluogullari CA, Balkan F, et al. Role of serum levels of irisin and oxidative stress markers in pregnant women with and without gestational diabetes. Gynecol Endocrinol. 2017; 33(5): 405–407.
  37. Chen CY, Tsai WL, Lin PJ, et al. The value of serum ischemia-modified albumin for assessing liver function in patients with chronic liver disease. Clin Chem Lab Med. 2011; 49(11): 1817–1821.
  38. D'souza JMP, Pai VR, Harish S, et al. IMA and IMAR in serum and saliva of preeclampsia--a preliminary study. Hypertens Pregnancy. 2014; 33(4): 440–448.
  39. Beyazit F, Yilmaz N, Balci O, et al. Evaluation of Oxidative Stress in Women with Polycystic Ovarian Syndrome as Represented by Serum Ischemia Modified Albumin and Its Correlation with Testosterone and Insulin Resistance. Intern Med. 2016; 55(17): 2359–2364.
  40. Duarte MM, Rocha JBT, Moresco RN, et al. Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem. 2009; 42(7-8): 666–671.
  41. Bhakthavatsala Reddy C, Cyriac C, Desle HB. Role of "Ischemia Modified Albumin" (IMA) in acute coronary syndromes. Indian Heart J. 2014; 66(6): 656–662.